Defeat Duchenne Canada is pleased to share with our Canadian Duchenne community the latest release from Sarepta Therapeutics.

They recently announced the initiation of EMBARK and the advancement of the SRP-9001 program. This represents the first pivotal double-blind gene therapy trial in Duchenne, initiated in the US, Europe and Asia. Doug Ingram, CEO and president, said:

“The initiation of EMBARK represents the culmination of enormous effort and success from a research, development and manufacturing perspective and is an extraordinarily important moment for the patient community and a leap forward in our effort to change the course of Duchenne.”

We are encouraged by this news and the potential for more clinical trial options in Canada. We are discussing with our contacts at Roche Canada and Sarepta to see if and when Canadian sites may be added to the list and will keep you posted on any progress.

Click the button below to read the community letter.